Loading…
Reported covered position: Intern, United States House of Representatives
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1 / Public Law - ORPHAN Cures Act HR 1414 - Camerons Law HR 7148 / Public Law 119-75 - PRV Reauthorization CMS-5545-P - Global Benchmark for Efficient Drug Pricing (GLOBE) CMS-5546-P - Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Proclamation 11020 - Exemption for Orphan Drugs from 232 Pharmaceutical Tariffs Rare Disease Innovation Issues
Priority for Pediatric Cures Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2026 · third_quarter · Q3
H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2026 · second_quarter · Q2
Source: Senate LDA
H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit
Mikaela Naylon Give Kids a Chance Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit
HR 1 / Public Law - ORPHAN Cures Act HR 1414 - Camerons Law HR 7148 / Public Law 119-75 - PRV Reauthorization CMS-5545-P - Global Benchmark for Efficient Drug Pricing (GLOBE) CMS-5546-P - Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Proclamation 11020 - Exemption for Orphan Drugs from 232 Pharmaceutical Tariffs Rare Disease Innovation Issues
Scientific EXPERT Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit
Forest Service Accountability Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
Consolidated Appropriations Act, 2026
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1 / Public Law - ORPHAN Cures Act HR 1414 - Camerons Law HR 7148 / Public Law 119-75 - PRV Reauthorization CMS-5545-P - Global Benchmark for Efficient Drug Pricing (GLOBE) CMS-5546-P - Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Proclamation 11020 - Exemption for Orphan Drugs from 232 Pharmaceutical Tariffs Rare Disease Innovation Issues
Mikaela Naylon Give Kids a Chance Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
Scientific EXPERT Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit
Give Kids a Chance Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1 - Big Beautiful Bill Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1 - Big Beautiful Bill Act
Mikaela Naylon Give Kids a Chance Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 Rare Disease Exemption for Most Favored Nation Pricing Proposals
Mikaela Naylon Give Kids a Chance Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
Mikaela Naylon Give Kids a Chance Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals
Mikaela Naylon Give Kids a Chance Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
Scientific EXPERT Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1532 - Scientific EXPERT Act of 2025 S 822 - Scientific EXPERT Act of 2025
ORPHAN Cures Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
ORPHAN Cures Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities
ORPHAN Cures Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals
ORPHAN Cures Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities
ORPHAN Cures Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals
Scientific EXPERT Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1532 - Scientific EXPERT Act of 2025 S 822 - Scientific EXPERT Act of 2025
Give Kids a Chance Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
Give Kids a Chance Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities
Give Kids a Chance Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals
Give Kids a Chance Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 Rare Disease Exemption for Most Favored Nation Pricing Proposals
Accelerating Kids’ Access to Care Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 4758 - Accelerating Kids Access to Care Act
Creating Hope Reauthorization Act of 2024
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
ORPHAN Cures Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
Creating Hope Reauthorization Act of 2024
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
HR 1 / Public Law - ORPHAN Cures Act HR 1414 - Camerons Law HR 7148 / Public Law 119-75 - PRV Reauthorization CMS-5545-P - Global Benchmark for Efficient Drug Pricing (GLOBE) CMS-5546-P - Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Proclamation 11020 - Exemption for Orphan Drugs from 232 Pharmaceutical Tariffs Rare Disease Innovation Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2026 · first_quarter · Q1
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2025 · fourth_quarter · Q4
BIS-2025-0022 - Rare Disease Exemption for Pharmaceutical Tariffs CMS-5545-P - Rare Disease Exemption from GLOBE Model CMS-5546-P - Rare Disease Exemption from GUARD Model
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 Rare Disease Exemption for Most Favored Nation Pricing Proposals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2025 · third_quarter · Q3
HR 1 - Big Beautiful Bill Act
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals
Sec. 232 Pharmaceutical Tariffs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2025 · second_quarter · Q2
HR 1 - Big Beautiful Bill Act
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities
Executive Order 14297 - Impact of EO on Rare Disease Innovation Rare Disease Policy
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2025 · first_quarter · 1A
HR 4758 - Accelerating Kids Access to Care Act
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
HR 1532 - Scientific EXPERT Act of 2025 S 822 - Scientific EXPERT Act of 2025
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2025 · first_quarter · RR
Scientific research and education
Scientific research and education
Scientific research and education
Sec. 232 Pharmaceutical Tariffs
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Scientific research and education